Novo Nordisk Obesity Drug Data Sparks Questions On Valuation And Momentum [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Novo Nordisk's investigational obesity drug UBT251 has reported positive Phase 2 results over a 24 week trial. Patients in the study experienced meaningful weight loss, with the drug acting as a triple agonist targeting multiple hormone receptors. The update adds a new element to Novo Nordisk's GLP 1 obesity pipeline, which could matter for investors tracking the CPSE:NOVO B story. Novo Nordisk, traded as CPSE:NOVO B, is currently priced at DKK241.5, with a 1 year return of a 54.5% decline and a 5 year return of 24.7%. The new UBT251 data arrives after a period of weaker recent performance, with the stock showing a 26.9% decline year to date and a 21.5% decline over the past month. For investors, UBT251 adds another potential asset to watch within Novo Nordisk's obesity portfolio, alongside existing GLP 1 treatments. As the company progresses toward potent
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India [Yahoo! Finance]Yahoo! Finance
- Ozempic Is About to Go Generic in India, China and Canada [The New York Times]The New York Times
- Analysis-TrumpRx lists many medicines at prices higher than paid in UK [Yahoo! Finance]Yahoo! Finance
- Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says [CNBC]CNBC
- Novo Nordisk A/S (NVO) is now covered by Sanford C. Bernstein. They set an "outperform" rating and a $175.00 price target on the stock.MarketBeat
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/17/26 - Form 6-K
- 3/9/26 - Form 6-K
- 3/2/26 - Form 6-K
- NVO's page on the SEC website